Skip to main content
Top
Published in: PharmacoEconomics 3/2006

01-03-2006 | Editorial

Less is More: Medicines that Require Less Frequent Administration Improve Adherence, but Are They Better?

Author: Dr Dyfrig Hughes

Published in: PharmacoEconomics | Issue 3/2006

Login to get access

Excerpt

In recent years there has been an increase in the availability of medicines that require less frequent administration. Examples are diverse, and include once-weekly and once-monthly bisphosphonates for the treatment of postmenopausal osteoporosis; long-acting transdermal, implantable and injectable hormonal contraceptives; and fortnightly injectable risperidone for the management of schizophrenia. Medicines that require less frequent administration are more acceptable to patients and consequently result in better adherence. However, their use should be supported by evidence on whether the enhanced adherence translates to improved benefits in routine practice, and whether any such improvements justify the additional cost that may result. …
Literature
1.
go back to reference Urquhart J. The odds of the three nons when an aptly prescribed medicine isn’t working: non-compliance, non-absorption, nonresponse. Br J Clin Pharmacol 2002; 54: 212–220PubMedCrossRef Urquhart J. The odds of the three nons when an aptly prescribed medicine isn’t working: non-compliance, non-absorption, nonresponse. Br J Clin Pharmacol 2002; 54: 212–220PubMedCrossRef
2.
go back to reference Hughes DA, Bagust A, Haycox A, et al. The impact of noncompliance on the cost-effectiveness of pharmaceuticals: a review of the literature. Health Econ 2001; 10: 601–615PubMedCrossRef Hughes DA, Bagust A, Haycox A, et al. The impact of noncompliance on the cost-effectiveness of pharmaceuticals: a review of the literature. Health Econ 2001; 10: 601–615PubMedCrossRef
3.
go back to reference Haynes RB, Yao X, Degani A, et al. Interventions to enhance medication adherence. Cochrane Database Syst Rev 2005 Oct 19; (4): CD0000ll Haynes RB, Yao X, Degani A, et al. Interventions to enhance medication adherence. Cochrane Database Syst Rev 2005 Oct 19; (4): CD0000ll
4.
go back to reference Elliott RA, Barber N, Horne R. Cost-effectiveness of adherence-enhancing interventions: a quality assessment of the evidence. Ann Pharmacother 2005; 39: 508–515PubMedCrossRef Elliott RA, Barber N, Horne R. Cost-effectiveness of adherence-enhancing interventions: a quality assessment of the evidence. Ann Pharmacother 2005; 39: 508–515PubMedCrossRef
5.
go back to reference Claxton AJ, Cramer JA, Pierce C. A systematic review of the association between dose regimens and medication compliance. Clin Ther 2001; 23: 1296–1310PubMedCrossRef Claxton AJ, Cramer JA, Pierce C. A systematic review of the association between dose regimens and medication compliance. Clin Ther 2001; 23: 1296–1310PubMedCrossRef
6.
go back to reference Cramer JA, Amonkar MM, Hebborn A, et al. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005; 21: 1453–1460PubMedCrossRef Cramer JA, Amonkar MM, Hebborn A, et al. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005; 21: 1453–1460PubMedCrossRef
7.
go back to reference Richter A, Anton SE, Koch P, et al. The impact of reducing dose frequency on health outcomes. Clin Ther 2003; 25: 2307–2335PubMedCrossRef Richter A, Anton SE, Koch P, et al. The impact of reducing dose frequency on health outcomes. Clin Ther 2003; 25: 2307–2335PubMedCrossRef
8.
go back to reference Miller PD, McClung MR, Macovei L, et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 2005; 20: 1315–1322PubMedCrossRef Miller PD, McClung MR, Macovei L, et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 2005; 20: 1315–1322PubMedCrossRef
9.
go back to reference Trussell J. Contraceptive efficacy. In: Hatcher RA, Trussell J, Stewart F, et al., editors. Contraceptive technology. 18th ed. New York: Ardent Media, 2004 Trussell J. Contraceptive efficacy. In: Hatcher RA, Trussell J, Stewart F, et al., editors. Contraceptive technology. 18th ed. New York: Ardent Media, 2004
10.
go back to reference National Collaborating Centre for Women’s and Children’s Health. Long-acting reversible contraception: the effective and appropriate use of long-term reversible contraception. London: RCOG Press, 2005 National Collaborating Centre for Women’s and Children’s Health. Long-acting reversible contraception: the effective and appropriate use of long-term reversible contraception. London: RCOG Press, 2005
11.
go back to reference Ome P, Eerdekens M, Augustyns I, et al. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol 2005; 15: 111–117CrossRef Ome P, Eerdekens M, Augustyns I, et al. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol 2005; 15: 111–117CrossRef
12.
go back to reference Joint Formulary Committee. British national formulary. 50th ed. London: British Medical Association and Royal Pharmaceutical Society of Great Britain, 2005 [online]. Available from URL: http://www.bnf.org/bnf/ [Accessed 2006 Jan 23] Joint Formulary Committee. British national formulary. 50th ed. London: British Medical Association and Royal Pharmaceutical Society of Great Britain, 2005 [online]. Available from URL: http://​www.​bnf.​org/​bnf/​ [Accessed 2006 Jan 23]
13.
go back to reference Haycox A. Pharmacoeconomics of long-acting risperidone: results and validity of cost-effectiveness models. Pharmacoeconomics 2005; 23 Suppl. 1: 3–16PubMedCrossRef Haycox A. Pharmacoeconomics of long-acting risperidone: results and validity of cost-effectiveness models. Pharmacoeconomics 2005; 23 Suppl. 1: 3–16PubMedCrossRef
14.
go back to reference Wetzels GE, Nelemans P, Schouten JS, et al. Facts and fiction of poor compliance as a cause of inadequate blood pressure control: a systematic review. J Hypertens 2004; 22: 1849–1855PubMedCrossRef Wetzels GE, Nelemans P, Schouten JS, et al. Facts and fiction of poor compliance as a cause of inadequate blood pressure control: a systematic review. J Hypertens 2004; 22: 1849–1855PubMedCrossRef
15.
go back to reference Granger BB, Swedberg K, Ekman I, et al. Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. Lancet 2005; 366: 2005–2011PubMedCrossRef Granger BB, Swedberg K, Ekman I, et al. Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. Lancet 2005; 366: 2005–2011PubMedCrossRef
16.
go back to reference Urquhart J. Pharmacodynamics of variable patient compliance: implications for pharmaceutical value. Adv Drug Deliv Rev 1998; 33: 207–219PubMedCrossRef Urquhart J. Pharmacodynamics of variable patient compliance: implications for pharmaceutical value. Adv Drug Deliv Rev 1998; 33: 207–219PubMedCrossRef
17.
Metadata
Title
Less is More: Medicines that Require Less Frequent Administration Improve Adherence, but Are They Better?
Author
Dr Dyfrig Hughes
Publication date
01-03-2006
Publisher
Springer International Publishing
Published in
PharmacoEconomics / Issue 3/2006
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI
https://doi.org/10.2165/00019053-200624030-00001

Other articles of this Issue 3/2006

PharmacoEconomics 3/2006 Go to the issue

Correspondence

The Authors’ Reply

Adis Pharmacoeconomic Drug Evaluation

Bimatoprost